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The proinflammatory cytokine tumor necrosis factor alpha (TNF-a) induces lethal hepatitis when injected
into D-(1)-galactosamine-sensitized mice on the one hand or systemic inflammatory response syndrome (SIRS)
in normal mice on the other hand. We studied whether serum amyloid P component (SAP), the major acute-
phase protein in mice, plays a protective role in both lethal models. For this purpose, we used SAP0/0 mice
generated by gene targeting. We studied the lethal response of SAP0/0 or SAP1/1 mice to both lethal triggers
but found no differences in the sensitivity of both types of mice. We also investigated whether SAP is involved
in establishing two types of endogenous protection: one using a single injection of interleukin-1b (IL-1b) for
desensitization and clearly involving a liver protein, the other by tolerizing mice for 5 days using small doses
of human TNF-a. Although after IL-1b or after tolerization the SAP levels in the serum had risen fourfold in
the control mice and not in the SAP0/0 mice, the same extents of desensitization and tolerization were achieved.
Finally, we observed that the induction of hemorrhagic necrosis in the skin of mice by two consecutive local
injections with TNF-a was not altered in SAP0/0 mice. We conclude that the presence or absence of SAP has
no influence on the sensitivity of mice to TNF-a-induced hepatitis, SIRS, and hemorrhagic necrosis or on the
endogenous protective mechanisms of desensitization or tolerization.
Tumor necrosis factor alpha (TNF-a) is a pleiotropic cyto-
kine which exhibits a pronounced antitumor activity in vitro
as well as in vivo (2). However, administration of TNF-a has
proven to induce a systemic inflammatory response syndrome
(SIRS) (41). Administration of TNF-a in humans and in ex-
perimental animals gives rise to a shock-like response associ-
ated with hypotension and liver damage (5, 8, 19, 36). So far,
the application of TNF-a in a systemic treatment remains
impossible. Local treatment, however, has been achieved with
considerable success using the technique of isolated limb per-
fusion (23, 30). Also, the use of TNF-a in isolated hepatic
perfusion has recently been reported (10, 24).
In order to study TNF-a-induced hepatitis and SIRS, we
used murine TNF-a (mTNF-a) in D-(1)-galactosamine (GalN)-
sensitized or normal mice. GalN is a hepatotoxin which spe-
cifically inhibits transcription and translation in hepatocytes
(9). In combination with TNF-a, extreme apoptosis and necro-
sis of hepatocytes are observed (22, 25, 42). The mice die about
6 to 8 h after the challenge. TNF-a injection into normal mice
leads to lethal SIRS characterized by hypotension. In normal
mice, TNF-a causes lethality between 24 and 48 h after the
challenge, by a process resembling septic shock.
We are interested in identifying endogenous protective mol-
ecules and are focusing on the possible protective roles of
acute-phase proteins. In this context, we already described
protection conferred by a1-acid glycoprotein (25) and a1-anti-
trypsin (29). To induce feedback systems, we use two different
methods: (i) injection of a single dose of interleukin-1b (IL-
1b), which causes “desensitization,” which is most pronounced
against TNF-a–GalN (28, 43), and (ii) injection of a low dose
of human TNF-a (hTNF-a) twice daily for 5 days, which leads
to “tolerization” against TNF-a-induced SIRS (37). The mech-
anism of IL-1b-induced desensitization is not fully understood
but clearly involves induction of one or more factors in the
liver. An involvement of the liver in establishing tolerization
has not yet been demonstrated.
As IL-1b is a strong inducer of acute-phase proteins and
since serum amyloid P (SAP) component is one of the major
acute-phase proteins in mice, we investigated the role of SAP
in both TNF-a models and in the induction of desensitization
and tolerization. We also studied the effect of SAP presence or
absence in the induction of hemorrhagic necrosis by TNF-a.
To this end, we used recently generated SAP0/0 mice that have
no circulating SAP but are fertile and develop normally (3).
When such mice are treated with casein, they do not display
amyloid deposition, which is a typical feature of Alzheimer’s
disease (3).
MATERIALS AND METHODS
Animals. SAP0/0 mice were kindly provided by M. Botto and M. B. Pepys
(Immunological Medicine Unit, Royal Postgraduate Medical School, London,
United Kingdom). The SAP0/0 allele was backcrossed in a C57BL/6 background
for seven generations, after which heterozygotes were intercrossed; homozygous
SAP0/0 animals and homozygous wild types were identified by SAP enzyme-
linked immunosorbent assay (ELISA). No SAP was detected in the serum of
SAP0/0 mice by ELISA (3). ELISA has a sensitivity of approximately 10 ng/ml,
whereas normal basal levels found in wild-type C57BL/6 mice are approximately
10 mg/ml. Mutant and wild-type mice were then further bred as inbred couples.
Female offspring was used at the age of 8 to 12 weeks. The animals were housed
in a temperature-controlled, air-conditioned room with 12-h light-dark cycles
and received food and water ad libitum.
Reagents. mTNF-a and hTNF-a were expressed in Escherichia coli, produced
and purified to homogeneity in our laboratory, and had specific activities of 8.0 3
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107 and 1.8 3 107 IU/mg, respectively. The endotoxin levels, assessed with a
chromogenic Limulus amebocyte lysate assay (Coatest; Chromogenix, Stock-
holm, Sweden), were less than 10 endotoxin units (EU)/mg for both cytokine
preparations. mIL-1b was expressed in E. coli, was purified at our facilities, and
had a specific activity of 3.65 3 108 U/mg and an endotoxin contamination of
,10 EU/mg of protein. GalN was purchased from Sigma Chemical Co. (St.
Louis, Mo.).
Injections, blood collections, and SAP ELISA. Before injection, all reagents
were diluted in lipopolysaccharide-free phosphate-buffered saline (PBS). Intra-
peritoneal (i.p.) injections were 0.5 ml, and intravenous (i.v.) injections were 0.2
ml. Subcutaneous (s.c.) injections of TNF-a were 0.1 ml. Mice were bled at the
retroorbital plexus under light ether anesthesia. Serum was kept at 220°C.
Skin necrosis was induced by two s.c. injections of TNF-a into shaved mice. To
this end, mice were anesthetized using Avertine (tribromoethanol), and their
backs were shaved using an electric shaver and Veet 3 days before the injections.
SAP was measured by a sandwich ELISA as previously described (39). Briefly,
microtiter plates were coated overnight with a 1/1,000 dilution of a sheep anti-
mouse SAP (Calbiochem-Novabiochem International, San Diego, Calif.). After
washing, free places were blocked using 1% bovine serum albumin solution in
PBS (1 h at 37°C). Serum and a standard (Calbiochem-Novabiochem Interna-
tional) were diluted 25-fold, titrated in 1/5 steps in the assay in triplicates, and
incubated at 37°C for 3 h. After washing, the second antibody (a rabbit anti-
mouse SAP; Calbiochem-Novabiochem International) was added in a 1/5,000
dilution; the plates were incubated 1 h at 37°C, after which an anti-rabbit
antibody alkaline phosphatase-conjugated (Sigma Chemical Co.) was added and
incubated for another hour at 37°C. The assay was developed using p-nitrophe-
nylphosphate; absorption was measured at 405 nm.
Body temperatures and skin necrosis lesion size. Rectal body temperatures
were recorded with an electronic thermometer (model 2001; Comark Electron-
ics, Littlehampton, United Kingdom). The size of the skin lesions (in square
millimeters) was determined using calipers; the largest diameter and the per-
pendicular diameter were measured and multiplied.
Statistics. Mean values and the standard deviations were compared using an
unpaired Student’s t test. Final lethality was evaluated with a x2 test.
RESULTS
Response of SAP0/0 mice to TNF-a-induced lethality in
GalN-sensitized and normal mice. Before we studied the in-
volvement of SAP in desensitization and tolerization, we ex-
amined the effect of SAP deficiency in both models of TNF-
a-induced lethality. Therefore, mice were treated with 20 mg
of GalN given i.p. in combination with different doses of
mTNF-a. In C57BL/6 mice, the 100% lethal dose (LD100) is
usually obtained with 0.3 to 0.5 mg of TNF-a per mouse. In
Table 1, we show that both SAP1/1 and SAP0/0 mice are killed
by TNF-a in combination with GalN. No sensitization or pro-
tection were observed by the deletion of SAP.
To test the sensitivity to mTNF-a (without GalN sensitiza-
tion), SAP1/1 and SAP0/0 mice were injected i.v. with 2.5,
10, 20, or 30 mg of mTNF-a (the LD100 for C57BL/6 mice is
usually around 20 mg per mouse). Both SAP1/1 and SAP0/0
mice appeared to be equally sensitive to mTNF-a-induced
lethal shock (Table 1). These data show that the absence of
SAP does not lead to a changed response of mice to TNF-a-
induced hepatitis or TNF-a-induced lethal SIRS.
Role of SAP in IL-1b-induced desensitization. Desensitiza-
tion of mice to TNF-a–GalN is obtained by pretreatment with
IL-1b 12 h before the lethal challenge. As demonstrated in Fig.
1, serum levels of SAP are significantly (P , 0.0001) increased,
12 h after injection of 0.3 mg of IL-1b, in SAP1/1 mice only. In
order to study the role of SAP in IL-1b-induced desensitiza-
tion, SAP1/1 and SAP0/0 mice were injected i.p. with PBS or
different doses of IL-1b (3 to 300 ng per mouse), followed 12 h
later by an i.p. injection with 0.5 mg of mTNF-a/20 mg of GalN.
For this batch of mice, this dose appeared to be slightly less
than LD100. As demonstrated in Table 2, SAP
0/0 mice can be
desensitized just as well as SAP control mice. Also, regarding
protection against a TNF-a–GalN-induced drop in body tem-
perature, IL-1b was as active in SAP0/0 mice as in SAP1/1 mice
(data not shown). These data indicate that in the absence of
SAP, IL-1b is also perfectly able to desensitize to TNF-a–
GalN-induced lethal hepatitis.
FIG. 1. Induction of SAP in the serum of IL-1b-desensitized or hTNF-a-
tolerized mice. SAP was determined by ELISA and is expressed as a percentage
of the control (PBS-treated mice 5 100%). A total of 0.3 mg of IL-1b was
injected i.p., and SAP was measured 12 h later. hTNF-a was injected twice per
day for 5 days, and SAP was measured 3 days later. p, P 5 0.001; pp, P , 0.001
(n 5 6 in all groups).
TABLE 1. Response of SAP0/0 and SAP1/1 mice to
TNF-a–GalN- or mTNF-a-induced lethality
Challenge dose(s)a
Lethalityb (no. of animals
killed/total no.)
SAP1/1 SAP0/0 (P)
0.01 mg of mTNF-a 1 20 mg of GalN 0/6 0/6 (NS)
0.03 mg of mTNF-a 1 20 mg of GalN 4/6 5/6 (NS)
0.1 mg of mTNF-a 1 20 mg of GalN 5/6 5/6 (NS)
0.3 mg of mTNF-a 1 20 mg of GalN 6/6 6/6 (NS)
2.5 mg of mTNF-a 0/5 0/5 (NS)
10 mg of mTNF-a 8/10 5/6 (NS)
20 mg of mTNF-a 10/10 6/6 (NS)
30 mg of mTNF-a 10/10 6/6 (NS)
a TNF-a–GalN was given i.p., and mTNF-a was given i.v. (doses are per 20 g
of body weight).
b Lethality was scored for up to 48 h (no further deaths occurred). NS, not
significantly different from SAP1/1 control mice.
TABLE 2. IL-1b desensitizes SAP1/1 as well as SAP0/0 mice
to TNF-a–GalN-induced lethality
Pretreatmenta
Lethalityb (no. of animals killed/total no.)
SAP1/1 (P) SAP0/0 (P)
PBS 10/12 7/11
3 ng of IL-1b 6/7 (NS) 4/6 (NS)
30 ng of IL-1b 2/7** (0.0085) 3/5 (NS)
300 ng of IL-1b 0/6** (0.0004) 0/6* (0.0054)
a Pretreatment was given i.p. 12 h before the challenge.
b Challenge was 0.5 mg of mTNF-a plus 20 mg of GalN given i.p. (doses are per
20 g of body weight). Lethality was scored for up to 48 h (no further deaths
occurred). NS, not significantly different from PBS-pretreated mice. p and pp,
P , 0.01 and P , 0.001, respectively, versus PBS-pretreated mice.
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SAP is not involved in hTNF-a-induced tolerization. Repet-
itive injections of small doses of TNF-a for 1 week result in
tolerance to a normally lethal dose of TNF-a for a period of
about 10 days (37). Tolerization was induced by hTNF-a in-
jection (6 mg per injection) twice per day (9 a.m. and 6 p.m.)
for 5 consecutive days (Monday to Friday). The lethal chal-
lenge was given on day 8 (Monday). Just before the challenge,
blood was withdrawn and the serum SAP levels were mea-
sured. As demonstrated in Fig. 1, SAP levels had significant-
ly risen (P 5 0.001) in SAP1/1 mice and not in SAP0/0 mice.
Furthermore, SAP1/1 mice were indeed found to resist mTNF-
a-induced lethality by tolerization. In Table 3 we demonstrate
that hTNF-a is also able to induce tolerance in SAP0/0 mice.
These data indicate that SAP is not a necessary serum factor
for the induction of tolerance to TNF-a-induced SIRS.
Effect of SAP deficiency on TNF-a-induced hemorrhagic
skin necrosis. Two s.c. injections (with a 24-h interval) of 1 mg
of mTNF-a into the back of mice resulted in the appearance of
a local hemorrhagic necrotic spot 24 h after the second injec-
tion. This is a variation of the Shwartzman reaction as previ-
ously described (33). We treated SAP1/1 as well as SAP0/0
mice and measured the size of necrosis. We found that both
types of mice equally developed the typical erythema forma-
tion 24 h after the first injection, which developed further to a
necrotic spot 24 h after the second challenge. The size of the
spot was slightly (but not significantly, P 5 0.1774) less in
SAP0/0 mice than in controls (data not shown).
DISCUSSION
Phase I and phase II clinical trials, but also experiments
using laboratory animals, have revealed that the major dose-
limiting toxicities of a treatment with TNF-a are hypotension,
liver damage, and bowel necrosis (5, 8, 19, 36, 41). TNF-a is
indeed a powerful proinflammatory cytokine, and inhibition of
its inflammation-inducing properties will most likely also lead
to an increased therapeutic value of TNF-a in cancer treat-
ment. In our laboratory, we are predominantly studying two
different mouse models of TNF-a-induced lethality. In the first
model, recombinant mTNF-a is administered i.v. This leads to
SIRS associated with hypotension, hypothermia, massive ad-
hesion to the endothelium of neutrophils, and bowel necrosis,
eventually leading to lethal shock about 24 h after the chal-
lenge. In the second model, mice are treated with a combina-
tion of TNF-a and GalN, a liver-specific inhibitor of transcrip-
tion (9). In this model, mice are extremely sensitized to TNF-a,
and lethality appears to be the result of apoptosis and necrosis
of the liver (22, 42). This model resembles viral hepatitis (11,
20).
We believe that, in mammals, several endogenous feedback
mechanisms exist that are capable of reducing or preventing
(TNF-a-induced) inflammation and lethality. Because of the
extremely sensitizing effect of GalN (13, 21, 27) and of partial
hepatectomy (14), we hypothesize that at least part of these
feedback systems are located in the liver.
We are studying the molecular basis of two independent
protective feedback systems: desensitization and tolerance.
Desensitization is a short period of resistance to TNF-a or
TNF-a–GalN by a single injection of either TNF-a itself or
IL-1b (28, 43). We found that, very likely, IL-1b-induced de-
sensitization is the result of induction of one or more proteins
in the liver (28). In the liver, IL-1b is a strong inducer of the
acute-phase reaction, both by inducing IL-6 and by inducing
glucocorticoids (16, 26, 31, 40, 45). IL-6 is a cytokine that
directly provokes an acute-phase reaction and that induces
glucocorticoids (34). But the latter also induce an acute-phase
response (1). Induction, by IL-1, of both IL-6 and glucocorti-
coids simultaneously leads to a synergistic effect on the induc-
tion of the acute-phase response (7). We previously deter-
mined that indeed two of the acute-phase proteins, viz., a1-acid
glycoprotein and a1-antitrypsin, protect against both models of
TNF-a-induced lethality (25, 29, 42). Tolerance is induced by
repetitive treatment with TNF-a itself, given twice per day, for
5 days. After this treatment, mice are resistant to TNF-a- but
not to TNF-a–GalN-induced lethality. An involvement of the
liver has not been described (37, 38).
We describe here our efforts to further characterize the
factors that mediate the induction of desensitization as well as
tolerization. We have focused our attention on SAP because
the latter is, together with serum amyloid A protein, the major
acute-phase protein in the mouse. SAP belongs to the family of
pentraxins, which have been conserved throughout vertebrate
evolution. The homology to C-reactive protein, the classical
acute-phase protein in humans, is about 51%. In the mouse,
SAP is an acute-phase reactant, while it is constitutively
present in humans, with a maximal twofold increase during
sepsis (12). SAP shows calcium-dependent binding to DNA
(35), chromatin (18), and glycosaminoglycans (17). SAP has
also been described to play a role in the complement cascade
(4, 6, 15, 44). SAP0/0 mice were found to be protected against
induction of amyloidosis by injection of casein (3).
Using SAP0/0 mice, we found that the presence of SAP is
irrelevant to the sensitivity of the animals to a lethal challenge
of TNF-a–GalN or TNF-a. These data do not exclude a role of
SAP in the induction of protection by desensitization or toler-
ization. In fact, we found that after injection of a desensitizing
dose of IL-1b, as well as after tolerizing, at the moment the
challenge is given, serum SAP levels are significantly increased
(4- and 3.5-fold, respectively) in SAP1/1 mice only. However,
like SAP1/1 mice, SAP0/0 mice could very well be desensitized
and tolerized, despite the absence of SAP. These data illustrate
that SAP, though a major acute-phase reactant in the mouse
and a potential candidate as a mediator for desensitization and
tolerance, is not involved in both protective mechanisms.
We were also interested in studying the effect of SAP defi-
ciency in a model of TNF-a-induced skin hemorrhagic necrosis
since it has been reported that several strains of mice (BALB/c,
DBA/2, and A/J) had .10-fold-higher basal serum levels of
SAP compared to C57BL/6 mice (32) and that these strains
failed to develop typical necrosis (C. Libert, unpublished data).
However, a further decrease in SAP levels to zero in C57BL/6
mice by gene targeting and subsequent backcross in a C57BL/6
background did not lead to increased sensitivity to this TNF-a
effect as previously described.
In conclusion, we found no evidence for a protective role of
SAP in several models of TNF-a-induced inflammation or
lethal shock. Also, the induction of endogenous protection by
the processes of desensitization and tolerization appears to
occur in the absence of SAP.
TABLE 3. hTNF-a-induced tolerization to mTNF-a-induced
lethal shock in SAP1/1 and SAP0/0 mice
Pretreatmenta
Lethalityb (no. of animals killed/total no.)
SAP1/1 (P) SAP0/0 (P)
PBS 6/6 6/6
6 mg of hTNF-a 0/6** (0.0003) 1/6* (0.0017)
a Pretreatment was given i.p. twice a day for 5 consecutive days.
b Challenge was 25 mg of mTNF-a given i.v. at day 8 (doses are per 20 g of
body weight). Lethality was scored for up to 48 h (no further deaths occurred).
p and pp, P , 0.01 and P , 0.001, respectively, versus PBS-pretreated mice.
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